FDA’s Decision Boosts Fulcrum Therapeutics; Macy’s Beats Q2 Estimates
- August 22nd, 2023
- 373 views
Shares of Fulcrum Therapeutics, Inc. (Nasdaq: FULC) surged over 30% in pre-market trading following the announcement that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for FTX-6058, a potential treatment for sickle-cell disease (SCD).
$FULC was trading at $5.81 in pre-market, reflecting a gain of $1.89 (+48.21%).
Shifting focus, Macy’s, Inc. (NYSE: M) reported second quarter 2023 earnings at $0.26 per share, surpassing the consensus EPS estimate of $0.13. The company's quarterly sales amounted to $5.28 billion, slightly exceeding analysts' projected revenue of $5.09 billion.
In pre-market, $M was trading at $14.43, down $0.30 (-2.04%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login